AG
CRSP icon

Algert Global’s CRISPR Therapeutics CRSP Stock Holding History

Algert Global’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.61M Sell
96,820
-6,030
-6% -$318K 0.07% 463
2025
Q4 		$5.39M Buy
+102,850
New +$6.16M 0.08% 404
2024
Q4 		– Sell
-12,342
Closed -$580K – 1196
2024
Q3 		$580K Hold
12,342
– – 0.02% 875
2024
Q2 		$667K Buy
12,342
+3,832
+45% +$222K 0.02% 799
2024
Q1 		$580K Buy
+8,510
New +$609K 0.02% 743
2022
Q2 		– Sell
-16,943
Closed -$1.06M – 1231
2022
Q1 		$1.06M Buy
16,943
+9,420
+125% +$592K 0.07% 494
2021
Q4 		$570K Buy
7,523
+1,520
+25% +$133K 0.07% 485
2021
Q3 		$672K Buy
+6,003
New +$754K 0.09% 419

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return